Purchase this article with an account.
E. F. Kadrmas; Bromfenac for the Treatment of Chronic Pseudophakic Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1345.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the potential role of bromfenac in the treatment of chronic pseudophakic cystoid macular edema (CME).
Retrospective clinical and optical coherence tomography (OCT) analysis of 11 consecutive cases of CME unresponsive to treatment with ketorolac 0.4% q.i.d. following cataract surgery subsequently treated with bromfenac 0.09% b.i.d. as a single agent.
All 11 eyes treated with bromfenac showed complete clinical resolution of the CME with average visual improvement of 12.7 Snellen letters (S.E.M. 3.8 letters). All eyes showed complete resolution of macular edema by OCT line study analysis. The average decrease in central macular thickness and central macular volume measured 58.3 microns (S.E.M. 17.6 microns) and 0.18 mm3 (S.E.M. 0.05 mm3) respectively. Length of treatment with bromfenac averaged 20.1 weeks (Range: 10-40 weeks). Prior length of treatment with ketorolac averaged 23.0 weeks (Range: 9-50 weeks).
Bromfenac appears to be effective in the treatment of pseudophakic CME in cases refractory to treatment with ketorolac. Length of treatment is variable and may need to be prolonged to achieve the desired clinical outcome.
This PDF is available to Subscribers Only